Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Closed				5 and over				Other				ID03-0010 NCT00500578

Last Modified: 7/11/2007 First Published: 4/1/2001


2.		Phase III Randomized Study of Aerosolized Ribavirin With or Without Palivizumab in Patients With Respiratory Syncytial Virus Pneumonia Following Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				Any age				NCI				FHCRC-1379.00 NCI-G01-1929, NCT00014391

Last Modified: 11/1/2006 First Published: 5/1/2001


3.		Phase III Randomized Study of Aerosolized Ribavirin Versus Standard Supportive Therapy in Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				2 and over				NCI				FHCRC-1290.00 NCI-G01-1939, NCT00016081

Last Modified: 10/1/1993


4.		Phase II Pilot Study of Induction Therapy with Tiazofurin Followed by Maintenance Therapy with Ribavirin in Patients with Nonlymphoid Blast Crisis of Chronic Myelogenous Leukemia (Summary Last Modified 10/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				15 and over				NCI				UARK-92016 NCI-T92-0173O, T92-0173

Last Modified: 9/11/2008 First Published: 5/29/2008


5.		Study of the Effects of Immune-Modulating Therapies on Tissue Expression of Indoleamine 2, 3 dioxygenase in Patients With Untreated Acute or Chronic Hepatitis C, Metastatic Melanoma, or Crohn Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis				Completed				No age specified				NCI				VU-VICC-MEL-0651 VICC-MEL-0651, VU-VICC-060614

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute